CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Fesoterodine

弗斯特罗定 杂质对照品Fesoterodine Impurities

23 个杂质条目23 impurity entries

本页汇总 弗斯特罗定 的 23 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 23 impurity reference standards of Fesoterodine. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 弗斯特罗定(Fesoterodine)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesStability-Indicating RP-HPLC Method for the Estimation of Process-Related Impurities and Degradation Products in Fesoterodine Fumarate by Using a Mass Spectrometric Compatible Mobile Phase
    Journal of chromatographic science · 2021 · Kumar N et al.  ·  PMID 33190158  ·  DOI
  2. 杂质研究Impurity studiesFesoterodine stress degradation behavior by liquid chromatography coupled to ultraviolet detection and electrospray ionization mass spectrometry
    Talanta · 2011 · Sangoi MS et al.  ·  PMID 21530781  ·  DOI
  3. 杂质研究Impurity studiesDetermination of fesoterodine in a pharmaceutical preparation by a stability-indicating capillary zone electrophoresis method
    Journal of AOAC International · 2013 · Sangoi MS et al.  ·  PMID 24645509  ·  DOI
  4. 分析方法Analytical MethodsSecond-Order Derivative UV Spectrophotometric Method for the Determination of Fesoterodine and Comparison with LC, CE and LC-MS/MS in Commercial Extended-Release Tablets
    Acta chimica Slovenica · 2012 · Sangoi MS et al.  ·  PMID 24061183
  5. 分析方法Analytical MethodsDetermination of fesoterodine in pharmaceutical formulations by using liquid chromatography-tandem mass spectrometry
    European journal of mass spectrometry (Chichester, England) · 2010 · Sangoi MS, Steppe M  ·  PMID 21173462  ·  DOI

弗斯特罗定 —— 原料药与杂质对照品Fesoterodine — drug substance & impurities

共 23 个条目(含原料药本体)23 items incl. the drug substance
Fesoterodine Impurity 1(Fesoterodine Diol) structure
1
弗斯特罗定杂质1(弗斯特罗定二醇)Fesoterodine Impurity 1(Fesoterodine Diol)
Fesoterodine Impurity 1(Fesoterodine Diol)
CAS No.207679-81-0
Chemical FormulaC22H31NO2
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 1 Formate(Fesoterodine Diol Formate) structure
1
弗斯特罗定杂质1甲酸盐(弗斯特罗定二醇甲酸盐)Fesoterodine Impurity 1 Formate(Fesoterodine Diol Formate)
Fesoterodine Impurity 1 Formate(Fesoterodine Diol Formate)
CAS No.380636-49-7
Chemical FormulaC22H31NO2·CH2O2
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 3 structure
3
弗斯特罗定杂质3Fesoterodine Impurity 3
Fesoterodine Impurity 3
CAS No.1428856-46-5
Chemical FormulaC48H66N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 4 structure
4
弗斯特罗定杂质4Fesoterodine Impurity 4
Fesoterodine Impurity 4
CAS No.200801-70-3
Chemical FormulaC22H31NO2
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 5 structure
5
弗斯特罗定杂质5Fesoterodine Impurity 5
Fesoterodine Impurity 5
CAS No.1262778-55-1
Chemical FormulaC26H35NO4
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 6 structure
6
弗斯特罗定杂质6Fesoterodine Impurity 6
Fesoterodine Impurity 6
CAS No.1333234-71-1
Chemical FormulaC26H35NO3
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 7 structure
7
弗斯特罗定杂质7Fesoterodine Impurity 7
Fesoterodine Impurity 7
CAS No.1435768-96-9
Chemical FormulaC26H35NO3
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 8 structure
8
弗斯特罗定杂质8Fesoterodine Impurity 8
Fesoterodine Impurity 8
CAS No.1254942-29-4
Chemical FormulaC30H39NO6
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 9 structure
9
弗斯特罗定杂质9Fesoterodine Impurity 9
Fesoterodine Impurity 9
CAS No.250214-44-9
Chemical FormulaC26H37NO3·C4H4O4
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 10 structure
10
弗斯特罗定杂质10Fesoterodine Impurity 10
Fesoterodine Impurity 10
CAS No.895137-81-2
Chemical FormulaC26H37NO2
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 11 structure
11
弗斯特罗定杂质11Fesoterodine Impurity 11
Fesoterodine Impurity 11
CAS No.1208313-13-6
Chemical FormulaC30H43NO4
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 12 structure
12
弗斯特罗定杂质12Fesoterodine Impurity 12
Fesoterodine Impurity 12
CAS No.1390644-37-7
Chemical FormulaC26H35NO3
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 13 Fumarate((S)-Fesoterodine Fumarate) structure
13
弗斯特罗定杂质13 富马酸盐 ((S)-弗斯特 富马酸盐)Fesoterodine Impurity 13 Fumarate((S)-Fesoterodine Fumarate)
Fesoterodine Impurity 13 Fumarate((S)-Fesoterodine Fumarate)
CAS No.1431511-18-0
Chemical FormulaC30H43NO4·C4H4O4
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 16 structure
16
弗斯特罗定杂质16Fesoterodine Impurity 16
Fesoterodine Impurity 16
CAS No.1380491-71-3
Chemical FormulaC48H66N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 19 structure
19
弗斯特罗定杂质19Fesoterodine Impurity 19
Fesoterodine Impurity 19
CAS No.1312416-97-9
Chemical FormulaC16H18O3
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 21 structure
21
弗斯特罗定杂质21Fesoterodine Impurity 21
Fesoterodine Impurity 21
CAS No.260389-90-0
Chemical FormulaC22H31NO2
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 22 structure
22
弗斯特罗定杂质22Fesoterodine Impurity 22
Fesoterodine Impurity 22
CAS No.7322-88-5
Chemical FormulaC10H10O4
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 24 structure
24
弗斯特罗定杂质24Fesoterodine Impurity 24
Fesoterodine Impurity 24
CAS No.1428856-53-4
Chemical FormulaC30H39NO6
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 25 Fumarate structure
25
弗斯特罗定杂质25 富马酸盐Fesoterodine Impurity 25 Fumarate
Fesoterodine Impurity 25 Fumarate
CAS No.1428856-48-7
Chemical FormulaC30H43NO4·C4H4O4
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 25 structure
25
弗斯特罗定杂质25Fesoterodine Impurity 25
Fesoterodine Impurity 25
CAS No.250214-55-2
Chemical FormulaC30H43NO4
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 26 structure
26
弗斯特罗定杂质26Fesoterodine Impurity 26
Fesoterodine Impurity 26
CAS No.1208313-12-5
Chemical FormulaC26H37NO3
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 27 structure
27
弗斯特罗定杂质27Fesoterodine Impurity 27
Fesoterodine Impurity 27
CAS No.1312598-30-3
Chemical FormulaC26H37NO2
Purity>95%询价On request
10mg25mg50mg100mg
Fesoterodine Impurity 4-d14 structure
4-D14
弗斯特罗定杂质4-d14Fesoterodine Impurity 4-d14
Fesoterodine Impurity 4-d14
CAS No.1185071-13-9
Chemical FormulaC22H17D14NO2
Purity>95%询价On request

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

弗斯特罗定 —— 研究文献与合成路线Fesoterodine — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 弗斯特罗定 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Fesoterodine. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Stability-Indicating RP-HPLC Method for the Estimation of Process-Related Impurities and Degradation Products in Fesoterodine Fumarate by Using a Mass Spectrometric Compatible Mobile Phase
    Kumar N, Sangeetha D, Kalyanraman L · Journal of chromatographic science · 2021 · 被引 1cited 1
  2. Fesoterodine stress degradation behavior by liquid chromatography coupled to ultraviolet detection and electrospray ionization mass spectrometry
    Sangoi MS, Todeschini V, Steppe M · Talanta · 2011 · 被引 10cited 10
  3. PROCESS FOR THE PREPARATION OF FESOTERODINE WITH LOW IMPURITIES CONTENT
    ARTICO MARCO, ATTOLINO EMANUELE, ALLEGRI PIETRO · 2011
  4. A process for the preparation of fesoterodine with low impurities content
    ARTICO MARCO, ATTOLINO EMANUELE, ALLERGRINI PIETRO · 2011
  5. Fesoterodine Substantially Free of Dehydroxy Impurity
    NEELA PRAVEEN KUMAR, CHARUGUNDLA KISHORE, KUMAR UDHAYA, et al. · 2011
  6. Determination of fesoterodine in a pharmaceutical preparation by a stability-indicating capillary zone electrophoresis method
    Sangoi MS, Todeschini V, Steppe M · Journal of AOAC International · 2013 · 被引 1cited 1

合成与制备工艺专利Synthesis & process patents

  1. PROCESSES FOR THE PREPARATION OF FESOTERODINE
    DWIVEDI SHRIPRAKASH DHAR, PRASAD ASHOK, JAIN KULDEEP NATWARLAL · 公开号 WO2012025941WO2012025941 · 2012
  2. PREPARATION PROCESS OF FESOTERODINE AND INTERMEDIATES
    JAIN RAJESH, RAO SIRIPRAGADA MAHENDER, RAO JAGADEESHWAR R, MADADA CHANDRA RAO · 公开号 WO2011158257WO2011158257 · 2011
  3. PROCESS FOR THE PREPARATION OF FESOTERODINE
    MANTEGAZZA SIMONE, ALLEGRINI PIETRO, ATTOLINO EMANUELE · 公开号 US2011105783US2011105783 · 2011
  4. Method for preparing fesoterodine and/or fesoterodine fumarate
    CIAMBECCHINI UMBERTO, ULLUCCI ELIO, TURCHETTA STEFANO, ZENONI MAURIZIO · 公开号 EP2251317EP2251317 · 2010
  5. Method for preparing fesoterodine and/or fesoterodine fumarate
    CIAMBECCHINI UMBERTO, ULLUCCI ELIO, TURCHETTA STEFANO, ZENONI MAURIZIO · 公开号 US2010292503US2010292503 · 2010

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

弗斯特罗定 杂质谱研究要点Fesoterodine — impurity profiling notes

下面这些是拿到 弗斯特罗定 的 23 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 23 impurity entries for Fesoterodine, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances